单克隆B细胞淋巴细胞增多症和慢性淋巴细胞白血病患者发生静脉血栓栓塞的发生率、危险因素和结局
基于Mayo Clinic CLL数据库纳入1998至2021年新诊断MBL/CLL患者946例,80例发生VTE,年发生率约1%。既往VTE史(HR 5.33)和高/极高危CLL-IPI评分(HR 2.63)与VTE风险升高相关,VTE与更短总生存相关(HR 1.82);无VTE史患者VTE发生率为一般人群的5.9倍。
要点
- 新诊断MBL/CLL患者VTE年发生率约1%。
- 既往VTE史和高/极高危CLL-IPI评分与VTE风险升高相关。
- MBL/CLL患者VTE发生率约为年龄性别匹配一般人群的5.9倍。
核心结论
- 研究显示MBL/CLL患者VTE风险较年龄和性别匹配的一般人群增加约6倍。
研究设计与样本
- 使用Mayo Clinic CLL数据库识别1998年至2021年间新诊断MBL/CLL患者946例。
- 通过查询电子健康记录中VTE特异性ICD-9和ICD-10编码并复核影像学检查结果确定VTE发生。
主要发现
- 80例患者发生VTE,新诊断MBL/CLL患者VTE年发生率约1%。
- 多变量分析中,既往VTE史与VTE风险升高相关(HR 5.33;95% CI 1.93-14.68,P=.001)。
- 高/极高危CLL-IPI评分与VTE风险升高相关(HR 2.63;95% CI 1.31-5.26,P=.006)。
- 接受CLL治疗或发生非血液系统恶性肿瘤与VTE风险升高无关。
- 调整年龄、性别、既往VTE史和Rai分期后,发生VTE与更短总生存相关(HR 1.82,95% CI 1.30-2.55)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The incidence, risk factors, and outcomes of venous thromboembolism (VTE) in patients with chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis (MBL) are not well described. OBJECTIVES: We aimed to determine the clinical characteristics, risk factors, and outcomes of incident VTE in patients with newly diagnosed MBL/CLL and compare the incidence to the age- and sex-matched general population. METHODS: Using the Mayo Clinic CLL Database, we identified 946 patients with newly diagnosed MBL/CLL between 1998 and 2021. Incidence of VTE was identified by querying the electronic health record for VTE-specific International Classification of Diseases-9 and -10 codes and reviewing results of radiographic studies. RESULTS: Eighty patients developed VTE. The incidence of VTE in patients with newly diagnosed MBL/CLL was ∼1% per year. In multivariable analyses, prior history of VTE (hazard ratio [HR]: 5.33; 95% CI: 1.93-14.68, P = .001) and high/very high-risk CLL-International Prognostic Index score (HR: 2.63; 95% CI: 1.31-5.26; P = .006) were associated with an increased risk of VTE; receipt of CLL treatment or occurrence of nonhematologic malignancy was not. Development of VTE was associated with shorter overall survival (HR: 1.82, 95% CI: 1.30-2.55) after adjusting for age, sex, prior history of VTE, and Rai stage. The age- and sex-adjusted VTE incidence rate for patients with MBL/CLL and no prior history of VTE (n = 904) was 1254 per 100 000 person-years compared with 204 per 100 000 person-years in the general population, reflecting a 5.9-fold increase. CONCLUSION: Our study demonstrates a 6-fold increased risk of VTE in patients with MBL/CLL compared with the age- and sex-matched general population.
引用
- Koehler AB, Rabe KG, Crusan DJ, et al. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2024. PMID: 39343103. doi:10.1016/j.jtha.2024.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。